Phenotypes associated with this allele

• Allele Symbol: Tg(tetO-GFP,-APOL1*)#Susz
• Allele Name: transgene insertion, Katalin Susztak
• Allele ID: MGI:6331300
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(Pax8-rtTA2S*M2)1Koes/0 Tg(tetO-GFP,-APOL1*)#Susz/0	involves: C57BL/6 * DBA * FVB/N	MGI:6331385
cx2	Tg(Nphs1-rtTA*3G)8Jhm/0 Tg(tetO-GFP,-APOL1*)#Susz/0	involves: C57BL/6J * CBA/J * FVB/N	MGI:6331363

Genotype
MGI:6331385

cx1

• Allelic Composition: Tg(Pax8-rtTA2S*M2)1Koes/0; Tg(tetO-GFP,-APOL1*)#Susz/0
• Genetic Background: involves: C57BL/6 * DBA * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:251848 )

N • serum creatinine, blood urea nitrogen and urinary albumin-to-creatinine ratio measurements are not altered

Genotype
MGI:6331363

cx2

• Allelic Composition: Tg(Nphs1-rtTA*3G)8Jhm/0; Tg(tetO-GFP,-APOL1*)#Susz/0
• Genetic Background: involves: C57BL/6J * CBA/J * FVB/N

mortality/aging

premature death ( J:251848 )

• increase in mortality rate in doxycycline-treated mice

homeostasis/metabolism

uremia ( J:251848 )

• azotemia in doxycycline-treated mice

increased circulating creatinine level ( J:251848 )

• increase in serum creatinine in doxycycline-treated mice

increased blood urea nitrogen level ( J:251848 )

• increase in serum blood urea nitrogen (BUN) in doxycycline-treated mice

albuminuria ( J:251848 )

• doxycycline-treated mice exhibit albuminuria, as indicated by higher urinary-albumin-to-creatinine ratio level

• mice treated with doxycycline for 14 days and then taken off it for 7 or 17 days, show halted albuminuria development

renal/urinary system

albuminuria ( J:251848 )

• doxycycline-treated mice exhibit albuminuria, as indicated by higher urinary-albumin-to-creatinine ratio level

• mice treated with doxycycline for 14 days and then taken off it for 7 or 17 days, show halted albuminuria development

abnormal podocyte morphology ( J:251848 )

• marker analysis indicated severe podocyte dedifferentiation in doxycycline-treated mice

podocyte foot process effacement ( J:251848 )

• doxycycline-treated mice exhibit increased foot-process effacement

decreased podocyte number ( J:251848 )

• podocyte number is reduced in doxycycline-treated mice

podocyte vacuoles ( J:251848 )

• increase in number of multivesicular bodies, amphisomes, and autophagosomes in podocytes of doxycycline-treated mice

• the ratio of autophagic vacuoles to autolysosomes is increased in podocytes of doxycycline-treated mice, indicating an increase in autophagic vacuole content

glomerulosclerosis ( J:251848 )

• doxycycline-treated mice show an increase in global and segmental glomerulosclerosis

• by 3 weeks after doxycycline induction, mice develop severe global and segmental sclerosis

abnormal podocyte physiology ( J:251848 )

• podocytes from doxycycline-treated mice show increased inflammatory cell death (pyroptosis)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
kidney disease		DOID:557		J:251848